EV/DNG (Qlaira, BAY86-5027)
EV/DNG (Qlaira, BAY86-5027) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy
Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction
Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects
Clinical Trials (5)
Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy
Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction
Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5